AN2 Therapeutics, Inc. Investment Income, Interest
AN2 Therapeutics, Inc. (ANTX) reported Investment Income, Interest of $720.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- AN2 Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $720.00K, a 4.51% decline year-over-year.
- AN2 Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $523.00K, a 41.10% decline year-over-year.
- AN2 Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $605.00K, a 43.77% decline year-over-year.
- AN2 Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $687.00K, a 45.78% decline year-over-year.
- AN2 Therapeutics, Inc. investment income, interest for fiscal 2025 was $2.93M, a 46.32% decline from fiscal 2024.
- AN2 Therapeutics, Inc. investment income, interest for fiscal 2024 was $5.47M, a 12.47% increase from fiscal 2023.
- AN2 Therapeutics, Inc. investment income, interest for fiscal 2023 was $4.86M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month | Investment Income, Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $720.00K 10-Q · filed 2026-08-11 | $1.24M 10-Q · filed 2026-08-11 | $1.85M derived: sum of 3 quarters · filed 2026-08-11 | $2.54M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $523.00K 10-Q · filed 2026-05-11 | $1.13M derived: sum of 2 quarters · filed 2026-05-11 | $1.81M derived: sum of 3 quarters · filed 2026-05-11 | $2.57M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $605.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.29M derived: sum of 2 quarters · filed 2026-03-17 | $2.05M derived: sum of 3 quarters · filed 2026-08-11 | $2.93M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $687.00K 10-Q · filed 2025-11-12 | $1.44M derived: sum of 2 quarters · filed 2026-08-11 | $2.33M 10-Q · filed 2025-11-12 | $3.40M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $754.00K 10-Q · filed 2026-08-11 | $1.64M 10-Q · filed 2026-08-11 | $2.72M derived: sum of 3 quarters · filed 2026-08-11 | $3.98M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $888.00K 10-Q · filed 2026-05-11 | $1.96M derived: sum of 2 quarters · filed 2026-05-11 | $3.23M derived: sum of 3 quarters · filed 2026-05-11 | $4.68M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.34M derived: sum of 2 quarters · filed 2026-03-17 | $3.79M derived: sum of 3 quarters · filed 2026-03-17 | $5.47M 10-K · filed 2026-03-17 | $5.47M 10-K · filed 2025-03-25 |
| 2024-09-30 | $1.27M 10-Q · filed 2025-11-12 | $2.71M derived: sum of 2 quarters · filed 2025-11-12 | $4.39M 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $1.45M 10-Q · filed 2025-08-12 | $3.12M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $1.68M 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | $4.86M 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |